Department of Medicine, Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland.
Gastroenterol Clin North Am. 2012 Dec;41(4):805-19. doi: 10.1016/j.gtc.2012.08.005.
Irritable bowel syndrome (IBS) and chronic constipation (CC) are common problems worldwide and are associated with significant impact on activities of daily living and quality of life. Recent interest, in IBS in particular, has focused on the potential roles of the microbiota and its interaction with the host's immune system. Recently, high-quality clinical trials have been performed on prebiotics and probiotics in IBS or CC. Although strategies that seek to modify the microbiota, such as the use of probiotics, offer much promise in IBS and CC, more high-quality trials and, studies of longer duration are required.
肠易激综合征(IBS)和慢性便秘(CC)是全球常见的问题,对日常生活和生活质量有重大影响。最近,人们对 IBS 特别感兴趣,关注了微生物组及其与宿主免疫系统的相互作用的潜在作用。最近,针对 IBS 或 CC 中的益生元和益生菌进行了高质量的临床试验。虽然旨在改变微生物组的策略,如使用益生菌,在 IBS 和 CC 中具有很大的前景,但还需要更多高质量的试验和更长时间的研究。